Twenty-seven species of bacteria and fungi, among the hundreds that live in people’s mouths, have been collectively tied to a 3.5 times greater risk of developing pancreatic cancer, according to a study led by NYU Langone Health and its Perlmutter Cancer Center.
A team of scientists at Sanford Burnham Prebys and the University of Zurich in Switzerland identified a specific phosphoinositide kinase called PI5P4Kα as critical to supporting the unique demands of pancreatic ductal adenocarcinoma cells.
Glioblastoma cells that “cluster” together with other cells of the same type are less deadly than those that disperse from these clusters, according to findings from researchers at the Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.
The ZUMA-24 phase II clinical trial demonstrates the safety and feasibility of administering Yescarta (axi-cel) in the outpatient setting when treating relapsed or refractory large B-cell lymphoma.
Researchers from UVA Cancer Center, the University of Virginia School of Medicine, and Inova Peterson Life with Cancer detail the many ways artificial intelligence could help ensure patients receive the support they need.
A novel method could test for prostate cancer using biomarkers present in urine, according to the findings from a diagnostic case control study.
When it comes to their survival, cancer cells have a host of backup plans.
FDA approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
FDA approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) injections, biosimilars of Prolia and Xgeva respectively, for the treatment of osteoporosis. In addition, FDA granted provisional interchangeability designation for both Bosaya and Aukelso.
FDA approved selumetinib (Koselugo) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
